Think from memory the final two payments to Boneyard are due in March and September, so cash will be used to clear that for now.
The discount rate used to value biological assets is 20%, so means NTA makes a good rough bottom line for valuing (assuming most investors here like a generous margin for error in purchase price when dealing with micro-caps)
Ann: 31 December 2021 Interim Financial Report, page-21
Add ATP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.86M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $42.99K | 380.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 58000 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 423831 | 5 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| ATP (ASX) Chart |